The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by Chardan Capital on November 5, 2024. The analyst firm set a price target for $12.00 expecting EDIT to rise to within 12 months (a possible 405.26% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ:EDIT) was provided by Chardan Capital, and Editas Medicine maintained their buy rating.

The last upgrade for Editas Medicine Inc happened on August 8, 2024 when B of A Securities raised their price target to $15. B of A Securities previously had a neutral for Editas Medicine Inc.

The last downgrade for Editas Medicine Inc happened on October 17, 2023 when Cantor Fitzgerald changed their price target from N/A to N/A for Editas Medicine Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a maintained with a price target of $12.00 to $12.00. The current price Editas Medicine (EDIT) is trading at is $2.38, which is out of the analyst’s predicted range.